Regen BioPharma Inc. | Income Statement
Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
192.00
100.00
110.00
100
SG&A Expense
319.80
706.40
2,171.30
3,057.00
2,635.90
1,525.80
EBIT
319.80
706.40
-
-
2,525.90
1,425.80
Unusual Expense
-
-
210.90
411.30
2,792.80
1,742.10
Non Operating Income/Expense
35.20
48.00
-
-
53.90
5.80
Interest Expense
-
2.20
21.70
46.40
576.10
1,563.40
Pretax Income
355.00
756.40
2,210.70
3,413.50
5,839.00
4,715.20
Consolidated Net Income
355.00
756.40
2,210.70
3,413.50
5,839.00
4,715.20
Net Income
355.00
756.40
2,210.70
3,413.50
5,839.00
4,715.20
Net Income After Extraordinaries
355.00
756.40
2,210.70
3,413.50
5,839.00
4,715.20
Net Income Available to Common
355.00
756.40
2,210.70
3,413.50
5,839.00
4,715.20
EPS (Basic)
0.02
0.01
0.03
0.03
0.04
0.03
Basic Shares Outstanding
18,950.00
51,731.10
88,185.10
127,840.10
141,426.40
152,091.30
EPS (Diluted)
0.02
0.01
0.03
0.03
0.04
0.03
Diluted Shares Outstanding
18,950.00
51,731.10
88,185.10
127,840.10
141,426.40
152,091.30
EBITDA
319.80
706.40
1,979.30
2,957.00
2,525.90
1,425.80
Non-Operating Interest Income
-
0.20
1.10
1.20
1.90
10.20
About Regen BioPharma
View Profile
